Last reviewed · How we verify
Heparin Sodium In Plastic Container (Heparin Sodium)
Heparin Sodium In Plastic Container (generic name: Heparin Sodium) is a Anticoagulant Oligosaccharide drug developed by Fresenius Kabi. It is currently FDA-approved (first approved 1939) for Deep Vein Thrombosis with Pulmonary Embolism, Deep venous thrombosis, Disseminated intravascular coagulation.
Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa.
Heparin Sodium Injection is a parenteral anticoagulant that enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa, indicated for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and other thromboembolic conditions. The drug has immediate onset after intravenous administration with dose-dependent half-life of 0.5-2 hours and is contraindicated in patients with heparin-induced thrombocytopenia, active bleeding, or inability to monitor coagulation parameters. Significant drug interactions exist with antiplatelet agents and oral anticoagulants, requiring dose adjustments and careful monitoring to reduce bleeding risk. Heparin remains a cornerstone anticoagulant therapy with well-established efficacy and manageable safety profile when appropriately monitored.
At a glance
| Generic name | Heparin Sodium |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Anticoagulant |
| Target | Antithrombin III; Coagulation Factors Xa and IIa |
| Modality | Oligosaccharide |
| Phase | FDA-approved |
| First approval | 1939 |
Mechanism of action
Heparin interacts with the naturally occurring plasma protein Antithrombin III, inducing a conformational change that markedly enhances its serine protease activity. This enhanced activity inhibits activated coagulation factors involved in the clotting sequence, particularly Factor Xa and Factor IIa (thrombin). Small amounts of heparin inhibit Factor Xa, while larger amounts inhibit thrombin. Heparin also prevents the formation of stable fibrin clots by inhibiting the activation of the fibrin stabilizing factor. Importantly, heparin does not have fibrinolytic activity and therefore cannot lyse existing clots.
Approved indications
- Deep Vein Thrombosis with Pulmonary Embolism
- Deep venous thrombosis
- Disseminated intravascular coagulation
- Maintain Patency of Indwelling Vascular Catheter
- Non-Q wave myocardial infarction
- Peripheral Arterial Thromboembolism Prevention
- Peripheral arterial embolism
- Prevention of Cardiac Ischemia in Unstable Angina
- Prevention of Ischemic Complications of Non-Q Wave MI
- Prevention of Recurrent Venous Thrombosis Associated with Malignancy
- Prevention of deep vein thrombosis
- Pulmonary Thromboembolism Prevention
- Pulmonary thromboembolism
Common side effects
- Bleeding complication
- Wound complication
Serious adverse events
- Adrenal hemorrhage with acute adrenal insufficiency
- Ovarian hemorrhage (corpus luteum)
- Retroperitoneal hemorrhage
- Skin necrosis at injection site
- Anaphylactoid reactions including shock
- Asthma
- Heparin resistance
- Osteoporosis (long-term high dose)
- Cutaneous necrosis (systemic)
- Priapism
Drug interactions
- Oral anticoagulants (dicumarol, warfarin sodium)
- Platelet inhibitors (NSAIDs, dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists)
- Digitalis, tetracyclines, nicotine, antihistamines
- Intravenous nitroglycerin
- Antithrombin III (human)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin Sodium In Plastic Container CI brief — competitive landscape report
- Heparin Sodium In Plastic Container updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI
Frequently asked questions about Heparin Sodium In Plastic Container
What is Heparin Sodium In Plastic Container?
How does Heparin Sodium In Plastic Container work?
What is Heparin Sodium In Plastic Container used for?
Who makes Heparin Sodium In Plastic Container?
What is the generic name of Heparin Sodium In Plastic Container?
What drug class is Heparin Sodium In Plastic Container in?
When was Heparin Sodium In Plastic Container approved?
What development phase is Heparin Sodium In Plastic Container in?
What are the side effects of Heparin Sodium In Plastic Container?
What does Heparin Sodium In Plastic Container target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III; Coagulation Factors Xa and IIa
- Manufacturer: Fresenius Kabi — full pipeline
- Indication: Drugs for Deep Vein Thrombosis with Pulmonary Embolism
- Indication: Drugs for Deep venous thrombosis
- Indication: Drugs for Disseminated intravascular coagulation
- Compare: Heparin Sodium In Plastic Container vs similar drugs
- Pricing: Heparin Sodium In Plastic Container cost, discount & access